AUG 7, 2026 · JOURNAL ARTICLE
Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy
Frontiers in Urology
Retrospective cohort study with propensity matching showing mortality and renal benefits of GLP-1RA versus comparators in a specific high-risk population, but limited by observational design, potential unmeasured confounding, and modest event numbers acknowledged by authors.
Reported
All-cause mortality (GLP-1RA vs D…HR 0.60 (95% CI 0.46–0.79)
MAKEs (GLP-1RA vs DPP-4i)HR 0.63 (95% CI 0.48–0.81)
Thrombotic events (GLP-1RA vs DPP…HR 0.53 (95% CI 0.32–0.89)